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Herpes simplex virus type 2 (HSV-2) is the main cause of genital herpes and infections are
common in the lower genital tract. Although neuronal and immune cells can be infected,
epithelial cells, and keratinocytes are the primary HSV-2 target cells. HSV-2 establishes
latency by evading the host immune system and its infection can also increase the
risk of HIV-1 sexual transmission. Our pervious study found that HSV-2 immediate
early protein ICP22, inhibited IFN-β production by interfering with the IRF3 pathway.
However, ICP22-null HSV-2 did not completely lose the capability of suppressing IFN-β
induction, suggesting the involvement of other viral components in the process. In this
study, by using an ex vivo cervical explant model, we first demonstrated that HSV-2
can indeed inhibit IFN-β induction in human mucosal tissues. We further identified
HSV-2 immediate early protein ICP27 as a potent IFN-β antagonist. ICP27 significantly
suppresses the Sendai virus or polyinosinic-polycytidylic acid-induced IFN-β production
in human mucosal epithelial cells, showing that ICP27 inhibits the IFN-β promoter
activation, and IFN-β production at both mRNA and protein levels. Additional studies
revealed that ICP27 directly associates with IRF3 and inhibits its phosphorylation and
nuclear translocation, resulting in the inhibition of IFN-β induction. Our findings provide
insights into the molecular mechanism underlying HSV-2 mucosal immune evasion, and
information for the design of HSV-2 mucosal vaccines.
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INTRODUCTION
Herpes simplex virus type 2 (HSV-2) is a large dsDNA virus belonging to the α-Herpesviridae
subfamily (1). HSV-2 is mainly transmitted by genital mucosa through sex, causing vesicles, and
ulcers after acute infection and can be transported to dorsal root or cranial nerve ganglia to establish
life-long latency (2, 3). According to a report by WHO, it is estimated that over 400 million
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people were infected with HSV-2 and 19.2 million new infections
occurred worldwide in 2012 (4). Due to the greater and more
fragile surface of the female reproductive tract, the risk of
infection with HSV-2 in females is higher than that in males (5).
Epidemiological studies have shown that HSV-2 infection can
increase the risk of HIV-1 infection by 3–4 fold (6), with several
mechanisms for this increased susceptibility being proposed.
For instance, although HSV-2 can infect skin epithelial cells,
immune cells and nerve cells, it initially infects mucosal epithelial
cells during sexual transmission (7), which may facilitate HIV-
1 transmission via perturbation of epithelial integrity. Due to
the high positive-incidence of HSV-2 and common routes of
transmission with HIV-1, HSV-2 mucosal infection and immune
escape has attracted increased attention.
A virus infection initially activates innate immunity through
recognition by host pattern recognition receptors (PRRs),
including Toll-like receptors (TLRs), RIG-I-like receptors (RLR),
and DNA sensors (8–10). These PRRs activate downstream
signaling pathways using common components TBK-1 and IKK-
ε, leading to the activation of IRF3 signaling (11). IRF3 is an
important transcription factor which regulates the expression of
type I interferons (IFNs) and IFN stimulate genes (ISGs). IRF3
exists as an inactive monomer in most cells. Upon activation,
IRF3 is phosphorylated and assembled into dimers, and then
translocated into the nucleus to initialize the transcription of
IFN-β (12). Type I IFNs are normally expressed at low levels,
and their expression can be enhanced through the JAK/STAT
signaling pathway during viral or bacterial infections, resulting
in the transcription activation of ISGs (13). The type I IFN family
consists of IFN-α, IFN-β, IFN-ε, IFN-κ, and IFN-ω (14), with
IFN-β being the most intensively investigated in antiviral innate
immunity (15).
During HSV-2 infection, the induction of type I IFNs
is extremely low (16), suggesting that HSV-2 has evolved
strategies to antagonize IFN production. However, our current
understanding of HSV-2 immune evasion is limited, whereas
a large number of studies focusing on HSV-1 indicate the
involvement of multiple countermeasures in subverting type
I IFN production (17, 18). Given that most of these studies
address how HSV-1 proteins interfere with IFN production
or/and signaling using various cell lines as models (17), whether
and how IFN induction is affected in the context of viral infection,
at the tissue level, remain elusive. It is known that HSV-2 and
HSV-1 exhibit substantial differences in latency and reactivation
patterns (19), implying that they may use distinct mechanisms to
counteract the host innate immunity. Previous studies by others
indicated that HSV-2 virion host shutoff (vhs) protein UL41
suppresses IFN-β expression in human genital epithelial cells
(20), while HSV-2 US2 activates NF-κB by binding to TAK1 (21).
Our previous study revealed that HSV-2 immediate early protein
Abbreviations: HSV-2, herpes simplex virus type 2; SeV, Sendai virus; Poly(I:C),
polyinosinic-polycytidylic acid; PEI, Polyethylenimine; DLR, dual luciferase
report; Co-IP, co-immunoprecipitation; RT-PCR, real-time quantitative PCR;
PRR, pattern recognition receptor; TLR, Toll-like receptor; RLR, RIG-I-like
receptor; ISG, IFN stimulate gene; FBS, fetal bovine serum; DMEM, Dulbecco’s
modified Eagle medium; ORF, open reading frame.
(IE), ICP22 (US1), inhibits IFN-β production by antagonizing the
association of IRF3 with the IFN-β promoter (22). Nevertheless,
we observed that ICP22-null HSV-2 did not completely lose the
inhibitory activity on IFN-β induction, while other IE proteins
including ICP27 (UL54) also appeared to inhibit the activation
of the IFN-β promoter, although the underlying mechanism
remains to be fully addressed.
Our current study focused on whether and how HSV-2 and its
IE protein ICP27, inhibit IFN-β production in mucosal epithelial
cells. We found that HSV-2 can inhibit IFN-β induction in
human cervical tissues. We further revealed that HSV-2 ICP27
significantly suppresses the Sendai virus or polyinosinic-
polycytidylic acid-induced IFN-β production in human
mucosal epithelial cells. Mechanistically, we demonstrated that
HSV-2 ICP27 directly associates with IRF3 and inhibits its
phosphorylation and nuclear translocation, resulting in the
inhibition of IFN-β induction.
MATERIALS AND METHODS
Cell Lines and Viruses
HEK 293T, HeLa, and ME180 cells were cultured in Dulbecco’s
modified Eagle medium (DMEM) (Hyclone), supplemented with
10% fetal bovine serum (FBS) (Gibico), 100 U/ml penicillin and
100 U/ml streptomycin (Genom). All cells were cultured at 37◦C
in a 5% CO2 incubator.
HSV-2 (G strain) was obtained from LGC standards and
propagated in Vero cells. The Sendai virus (SeV) was propagated
in embryonated eggs. Special pathogen-free embryonated
eggs (Beijing Merial Vital Laboratory Animal Technology
Corporation) were incubated at 37◦C for 12 days before
inoculation with 300 µl 100 HAU ml−1 SeV into the allantoic
cavity of 12-day-old embryonated eggs and then incubated at
37◦C for 72 h. SeV was collected from allantoic fluids and the
titers were measured by hemagglutination (HA) assay using
chicken red blood cells.
Isolation of Primary Human Mucosal
Epithelial Cells
All protocols involving human subjects were reviewed and
approved by the local Research Ethics Committee of Wuhan
Institute of Virology, Chinese Academy of Sciences. Informed
written consents from the human subjects were obtained in this
study, and informed written parental consents were obtained for
all participants under the age of 16.
Human cervical or foreskin tissues were obtained from
the Wuhan Children’s Hospital (Wuhan Maternal and Child
Healthcare Hospital), Tongji Medical College, Huazhong
University of Science & Technology. Tissues were washed
carefully with PBS and then minced into small pieces. Prepared
tissue pieces were incubated with 5–10ml Dispase II Solution
(25 U/ml Dispase II in PBS pH 7.4 without Ca/Mg) containing
penicillin and streptomycin. 10% FBS was then added to avoid
excess damage to cells. Following an incubation at 4◦C overnight,
peeled off epidermis was rinsed with PBS, and placed into 3–5ml
0.05% Trypsin with EDTA in a 50ml conical tube. After an
incubation in a 37◦C water bath for 15–30min with agitation
Frontiers in Immunology | www.frontiersin.org 2 February 2019 | Volume 10 | Article 290
Guan et al. HSV-2 ICP2 Inhibits IFN-β Production
every 5min, twice the EDTA volume of medium with 10%
FBS was added. The epidermal cells were released by inverting
the tube several times or by pipetting the suspension. The
cell/tissue solution was passed through a sterile sieve followed by
centrifugation. Cell pellets were resuspended in EpiLife medium,
and the isolated epithelial cells were cultured in 12-well plates at
37◦C in a 5% CO2 incubator.
Construction of Plasmids
Primers used for plasmid construction are listed in
Supplementary Table 1. The open reading frame (ORF) of
HSV-2 ICP27 was amplified from HSV-2 genomic DNA
extracted from HSV-2G strain by PCR. For some constructs,
an N-terminal Flag or HA was introduced by PCR. PCR
products were cloned into pcDNA3.1(+)/(-) (Invitrogen),
and the constructed expression plasmids were named ICP27,
ICP27-Flag, ICP27-HA, ICP27(1−138aa), ICP27(1−152aa), and
ICP27(1−302aa), respectively. All constructs were verified
by DNA sequencing (Sunny Biotechnology). The reporter
plasmid PRD(III-I)4-Luc was provided by Dr. Stephan Ludwig
(University of Muenster, Muenster, Germany). The reporter
plasmid p125-Luc and the internal control plasmid phRL-TK
were described previously (23). IRF3 and IRF3-5D expression
plasmids pIRES-hrGFP/IRF3-Flag and pIRES-hrGFP/IRF3-5D-
Flag (constitutively active mutant of IRF3) were provided by Dr.
Yiling Lin (Graduate Institute of Life Sciences, National Defense
Medical Center, Taiwan, China). pEF-Flag-RIG-IN (a carboxy-
terminally truncated, constitutively active RIG-I mutant)
expression plasmid was provided by Dr. Takashi Fujita (Kyoto
University, Kyoto, Japan). pcDNA3-MAVS-Flag expression
plasmid was provided by Dr. Hanzhong Wang (Wuhan Institute
of Virology, Wuhan, China). pcDNA3-TBK1-Flag and pcDNA3-
IKKε-Flag expression plasmids were provided by Dr. Katherine
Fitzgerald (University of Massachusetts Medical School,
Worcester, MA). Plasmids encoding influenza virus PR8/NS1
and HSV-2 ICP22, respectively, were described previously (22).
Dual Luciferase Report (DLR) Assay
HEK 293T cells were seeded in 24-well plates overnight and
co-transfected with empty vector or plasmid encoding HSV-2
ICP27, truncated HSV-2 ICP27 or influenza virus NS1, reporter
plasmid p125-Luc or PRD(III-I)4-Luc and internal control phRL-
TK. Transfections were performed using Lipofectamine 2000
(Life Technology, 11668019) according to the manufacturer’s
instructions. At 24 h post-transfection, cells were stimulated
with or without 100 HAU ml−1 SeV for 16 h. Cells were
harvested and lysed, and the lysates were used for measuring
firefly and Renilla luciferase activities using a Dual-luciferase
Reporter Assay System (Promega, E1980) according to the
manufacturer’s instructions. For some experiments, HEK 293T
cells were co-transfected with empty vector or ICP27 expression
plasmid, reporter plasmid p125-Luc and internal control phRL-
TK, together with plasmid encoding the IRF3 pathway inducer
RIG-IN, MAVS, TBK-1, IKK-ε, or IRF3-5D. At 40 h post-
transfection, the enzymatic activities of firefly and Renilla
luciferase were measured.
Immunoblot Assay
The proteins extracted from transfected or infected cells were
prepared using PierceTM IP Lysis Buffer (ThermoFisher
Scientific, 87787) supplemented with protein inhibitor
(cOmplete Protease Inhibitor Cocktail, 11697498001). The
protein samples were resolved by SDS-PAGE and transferred
onto PVDF membranes (0.45µm, Millipore). Cytoplasmic
and nuclear proteins were isolated using the Nuclear-Cytosol
Extraction Kit (Applygen, P1200-50).
The antibody (Ab) anti-HSV-1 ICP27+HSV-2 ICP27 was
purchased from Abcam (ab31631). Rabbit anti IRF3 Polyclonal
Antibody, Rabbit anti PCNA Ab and Mouse mAb anti HA-
tag were purchased from Proteintech (11312-1-AP, 10205-2-AP,
and 66006-1-Ig). Rabbit mAb against phospho-IRF-3 (Ser396)
was purchased from Cell Signaling Technology (4947S). Rabbit
mAb against HA-tag and Mouse mAb against Flag-tag were
purchased from Sigma-Aldrich (H6908 and F1804). Mouse mAb
anti β-actin was purchased from Santa Cruz Biotechnology
(sc81178). HRP-conjugated goat anti-rabbit IgG (H+L) and
HRP-conjugated goat anti-mouse IgG (H+L) were purchased
from ThermoFisher Scientific (ZB-2301 and ZB-2305). HRP-
conjugated mouse anti-rabbit IgG (Light Chain) was purchased
from Sangon Biotech (D110059-0100). Mouse IgG and Rabbit
IgG were purchased from BOSTER (BA1046 and BA1045). Alexa
Fluor 488-labeled Goat Anti-Mouse IgG (H+L), Alexa Fluor 647-
labeled Goat Anti-Rabbit IgG (H+L) andDAPI Staining Solution
were purchased from Beyotime (A0428, A0468, and C1006).
RNA Isolation and Quantitative PCR
The transfected cells were collected and total RNAs were
extracted using TRIzol (Invitrogen, 15596-026) according to the
manufacturer’s instructions. cDNA was synthesized by M-MLV
Reverse Transcriptase (Promega, M1705). The newly synthesized
cDNA was used as template for the amplification of IFN-β,
ISG15, ISG56, CXCL10, and GAPDH. The primer pairs for IFN-
β , ISG15, ISG56, CXCL0, and GAPDH were described previously
(22, 24). Relative real-time quantitative PCR (RT-PCR) was
performed on BioRad StepOne apparatus using a TransStart R©
Tip Green qPCR SuperMix (Transgen, AQ141-02), and GAPDH
was used as an internal control with conditions of 95◦C for
3min, followed by 40 cycles of 95◦C for 10 s, and 55◦C for
30 s. The expression difference was calculated on the basis of
2−11Ct values.
ICP27 Knockdown by siRNA
HSV-2 siRNA sequences were described previously (25), and
are listed in the Supplementary Table 1. All siRNAs were
synthesized by Eurofins Genomics. HeLa or ME180 cells
were seeded in 6-well plates overnight. Negative control or
siRNAs were transfected into HeLa or ME180 cells using
Lipofectamine 2000 (Life Technology, 11668019) according to
the manufacturer’s instruction. At 4 h post-transfection, HeLa
cells were infected with or without HSV-2 at an MOI of 1, or
ME180 cells at an MOI of 0.5. At 20 h post-infection, cells were
stimulated with or without 100 HAU ml−1 SeV for 16 h, and
supernatants were harvested for ELISA or cells were lysed for
DLR assay.
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Poly(I:C) Stimulation
HeLa or ME180 cells were seeded in 6-well plates overnight
and transfected with empty vector, HSV-2 ICP27 expression
plasmid, HSV-2 ICP22 expression plasmid or influenza virus
NS1 expression plasmid. At 24 h post-transfection, cells were
transfected with 2 µg/well Poly(I:C) (Sigma; P1530-25MG)
using Lipofectamine 2000 (Life Technology, 11668019) or mock-
transfected. At 16 h post-transfection, cells were lysed for DLR
assay or supernatants were harvested for ELISA.
ELISA for IFN-β
HEK 293T cells were seeded in 6-well plates overnight and
transfected with empty vector, HSV-2 ICP27 expression plasmid
or influenza virus NS1 expression plasmid. At 24 h post-
transfection, cells were stimulated with or without 100 HAU
ml−1 SeV for 16 h. Cell culture supernatants were collected
and centrifuged to remove cell debris. Fifty microliters of
supernatants were used for IFN-β detection using a VeriKineTM
Human IFN Beta ELISA Kit (PBL Assay Science, 41410)
according to the manufacturer’s instructions.
Immunofluorescence Assay
HeLa cells were seeded in 35mm glass-bottom dishes and
transfected with an empty vector, HSV-2 ICP27-HA expression
plasmid or an influenza virus NS1 expression plasmid. At
24 h post-transfection, HeLa cells were stimulated with or
without 100 HAU ml−1 SeV for 16 h. Cells were fixed with
4% paraformaldehyde and permeabilized with 0.2% Triton X-
100. After three washes with PBS, cells were blocked with
PBS containing 5% BSA for 1 h at room temperature, and
then incubated with rabbit anti-human IRF3 polyclonal Ab
and mouse anti HA-tag mAb at a dilution of 1:100 for 1 h
at room temperature. After three washes with PBS, cells were
incubated with Alexa Fluor 488-labeled Goat Anti-Mouse IgG
(H+L) and Alexa Fluor 647-labeled Goat Anti-Rabbit IgG (H+L)
at a dilution of 1:50 for 1 h at room temperature. Cells were
subsequently washed and incubated with DAPI solution for
10min at room temperature. Following the addition of 1ml
PBS into the dishes, cells were observed under a Multiphoton
Confocal Microscope (Nikon, A1 MP STORM).
Co-immunoprecipitation Assay
HEK 293T cells were seeded in 6-well plates and transfected with
ICP27-Flag plasmid or empty vector. At 24 h post-transfection,
cells were stimulated with or without 100HAUml−1 SeV for 16 h.
The proteins extracted from transfected cells were prepared using
PierceTM IP Lysis Buffer (ThermoFisher Scientific, 87787). Three
microgrammouse anti-Flag Ab or control mouse IgG was diluted
in 200 µl PBS with 0.2% Tween-20 (PBST) and added to fresh
Dynabeads protein G (Invitrogen, 10009D). After incubation
with rotation at 4◦C overnight, Dynabeads-Ab complexes were
washed once with 200 µl PBST before mixed with the samples,
followed by incubation at 4◦C overnight. The complexes were
washed three times with PBST, and target Ags were subjected to
Western Blot analysis after elution by boiling.
Binding Kinetic Analysis
HEK 293F cells were used for the expression and purification
of ICP27-Flag and IRF3-Flag. For every 1 × 106 cells, 1.5
µg expression plasmid was transfected into HEK 293F cells
using Polyethylenimine (PEI) transfection reagent (Polysciences,
23966-1). Cells were cultured in FreeStyle 293 Expression
Medium (Gibico, 12338018) at 37◦C in a 5% CO2 incubator
shaker at 135 rpm. At day 3 post-transfection, cells were
harvested and lysed by ultrasonic treatment. The Flag-tagged
protein was purified by Anti-DYKDDDDK G1 Affinity Resin
(GeneScript, L00432) and eluted with 3M NaCl. The purified
protein was concentrated in PBS using 30 kDa Centrifugal Filter
Units (Merck, UFC903008) for binding kinetic study.
The kinetics of binding was performed on a Forte-Bio Octet
Red System as described previously (26). This system monitors
interference of light reflected from the surface of a sensor to
measure the thickness of molecules bound to the sensor surface.
IRF3-Flag was conjugated with biotin at a molecular weight
ratio of 1:3 at room temperature for 1 h followed by washes,
and then concentrated in PBS to remove dissociative biotin.
10 microgram/milliliter biotinylated IRF3-Flag was coupled
to Biosenors (Fortebio, 18-5019) and immersed in different
concentration of ICP27-Flag (50, 200, 500, or 800 nM) for
association and disassociation. The response in nm shift was
recorded as a function of time.
Statistical Analysis
All experiments were repeated at least three times and the
data are presented as mean ± S.D., unless otherwise specified.
Data analyses were performed with GraphPad Prism 7 software
(GraphPad). A comparison between the two groups was analyzed
using a two tailed unpaired Student’s t-test. P < 0.05 was
considered statistically significant.
RESULTS
HSV-2 ICP27 Inhibits IFN-β Production in
Human Mucosal Epithelial Cells
HSV-2 evades mucosal innate immunity, but the underlying
mechanisms remain elusive (16). Our previous study showed
that HSV-2 immediate early protein ICP22 strongly inhibited
IFN-β production; however, knockout of ICP22 did not fully
abolish the inhibitory activity on IFN-β production in the context
of HSV-2 infection (22), while other IE proteins including
ICP27 (UL54) also appeared to be involved, but the underlying
mechanism remains to be fully investigated. In this study, we
performed experiments to assess whether HSV-2 ICP27 indeed
inhibits IFN-β induction, and if so, what is the underlying
mechanism. We first confirmed that IFN-β was expressed at
a very low level in HSV-2-infected human cervical tissues
(Figure 1A), informing that HSV-2 inhibits IFN-β induction
during mucosal infection. To assess the contribution of HSV-2
ICP27 in interfering with IFN-β induction, HEK 293T cells were
seeded in 24-well plates overnight and co-transfected with empty
vector pcDNA3.1(+), plasmid expressing HSV-2 ICP27 or the
positive control influenza virus NS1 together with the reporter
plasmid p125-Luc and the internal control phRL-TK. At 24 h
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post-transfection, cells were stimulated with or without 100 HAU
ml−1 SeV for 16 h. As shown in Figure 1B, HSV-2 ICP27 strongly
inhibited the activation of the IFN-β promoter. We subsequently
examined whether HSV-2 ICP27 inhibits the production of IFN-
β at mRNA or protein level. HEK 293T cells were seeded in 6-well
plates overnight and transfected with pcDNA3.1(+), plasmid
expressing HSV-2 ICP27 or the influenza virus NS1. At 24 h
post-transfection, cells were stimulated with or without 100 HAU
ml−1 SeV for 16 h. Total RNAs were extracted and IFN-β mRNA
was analyzed by RT-PCR. As shown in Figure 1C, HSV-2 ICP27
significantly inhibited the production of IFN-β mRNA. The level
of IFN-β proteins in the supernatants was measured by ELISA,
showing that HSV-2 ICP27 significantly inhibited the production
of INF-β at protein level (Figure 1D).
In addition to SeV stimulation, we also conducted
experiments under the condition of the IFN-β expression
induced by polyinosinic-polycytidylic acid [Poly(I:C)], an
artificial dsRNA sequence which can stimulate RIG-I signaling
pathway (27). HeLa cells were co-transfected with pcDNA3.1(+),
plasmid expressing HSV-2 ICP27, HSV-2 ICP22, or the influenza
virus NS1, together with the reporter plasmid p125-Luc and
the internal control phRL-TK. At 24 h post-transfection, cells
were stimulated with Poly(I:C) for 16 h and lysed for DLR
assay. The results revealed that HSV-2 ICP27 strongly inhibited
Poly(I:C)-induced activation of the IFN-β promoter (Figure 1E).
In addition, HeLa cells were transfected with pcDNA3.1(+),
plasmid expressing HSV-2 ICP27, HSV-2 ICP22, or the influenza
virus NS1. At 24 h post-transfection, cells were stimulated
with Poly(I:C) for 16 h, and supernatants were harvested for
ELISA. The results revealed that HSV-2 ICP27 strongly inhibited
Poly(I:C)-induced IFN-β induction at protein level (Figure 1F).
In addition, HSV-2 ICP27 also significantly inhibited Poly(I:C)
induced activation of the IFN-β promoter in ME180 cells
(Supplementary Figure 1A).
Impaired expression of type I IFNs leads to reduced expression
of the downstream interferons stimulated genes (ISGs) (28, 29).
To examine the impact of HSV-2 ICP27 on ISG expression, HEK
293T cells were transfected with empty vector pcDNA3.1(+) or
plasmid expressing HSV-2 ICP27, followed by stimulation with
SeV for 16 h. Total RNAs were extracted, and the mRNAs of ISGs
including ISG56, ISG15, and CXCL10 were analyzed by RT-PCR.
As shown in Figures 1G–I, HSV-2 ICP27 strongly inhibited the
expression of ISG56, ISG15, and CXCL10 at mRNA level.
Having demonstrated the critical role of HSV-2 ICP27 in
inhibiting IFN-β induction, we next conducted experiments to
examine the impact of HSV-2 ICP27 on IFN-β induction in the
context of HSV-2 infection. HeLa cells were co-transfected with
the reporter plasmid p125-Luc and the internal control phRL-
TK, together with negative control siRNA, ICP27 siRNA-1 or
ICP27 siRNA-2, followed by infection with HSV-2. Cells were
then stimulated with or without 100 HAU ml−1 SeV for 16 h
and lysed for DLR assay. As shown in Figure 2A, knockdown
of HSV-2 ICP27 by ICP27 siRNA-1 reduced the capability of
HSV-2 in inhibiting IFN-β production at promoter activation
level. To assess the impact of HSV-2 ICP27 on IFN-β production
at protein level, HeLa cells were treated with negative control
siRNA, ICP27 siRNA-1 or ICP27 siRNA-2, followed by infection
with HSV-2. At 24 h post-infection, supernatants were collected
for ELISA and cells were lysed for Western Blot. As shown
in Figure 2B, knockdown of HSV-2 ICP27 by ICP27 siRNA-1
reduced the capability of HSV-2 in inhibiting IFN-β production
at the protein level. Knockdown of HSV-2 ICP27 was detected
by a monoclonal antibody against HSV-2 ICP27, while β-actin
was used as an internal control (Figure 2C). We also found
that knockdown of HSV-2 ICP27 reduced the capability of
HSV-2 in inhibiting IFN-β promoter activation in ME180 cells
(Supplementary Figure 1B).
HSV-2 mainly infects epithelial cells and causes genital
herpes. In addition to human cervical tissue and cervicovaginal
epithelial cell lines, we performed experiments using primary
human foreskin epithelial cells. Human foreskin epithelial cells
were isolated and transfected with empty vector pcDNA3.1(+),
plasmid expressing HSV-2 ICP27 or ICP22, or infected with
HSV-2, followed by stimulation with or without 100 HAU
ml−1 SeV for 16 h. Total RNAs were extracted for RT-PCR
and supernatants were collected for ELISA. In primary human
foreskin epithelial cells, HSV-2 ICP27 significantly inhibited
SeV-induced IFN-β production at both mRNA (Figure 3A)
and protein (Figure 3B) levels. These results indicated that
HSV-2 ICP27 can inhibit IFN-β induction in primary mucosal
epithelial cells.
Altogether, the above findings inform that HSV-2 ICP27 plays
an essential role in interfering with the induction of IFN-β in
human cervical tissues, cervicovaginal epithelial cell lines, and
primary human mucosal epithelial cells.
HSV-2 ICP27 Inhibits IFN-β Production
Through IRF3 Signaling Pathway
HSV-1 ICP27 has recently been reported to inhibit type I IFNs
by interacting with STING-TBK1 complex in macrophages (30),
whereas our previous study found that HSV-2 can interrupts
RIG-I mediated IFN-β signaling pathway in human epithelial
cells (22). Given that DNA viruses produce dsRNAs during viral
replication, which can be recognized by RNA sensors like RIG-
I (31, 32), our current study focused on how HSV-2 ICP27
interferes with dsRNA-mediated induction of type I IFNs. We
first determined whether HSV-2 ICP27 affects the IRF3-mediated
signaling pathway. HEK 293T cells were seeded in 24-well plates
overnight and co-transfected with empty vector pcDNA3.1(+),
plasmid expressing HSV-2 ICP27 or the influenza virus NS1,
together with PRD(III-I)4-Luc which contains four repeats of
IRF3 responsive domain of the IFN-β promoter and the internal
control phRL-TK. At 24 h post-transfection, cells were stimulated
with or without 100 HAU ml−1 SeV for 16 h and lysed for DLR
assay. As shown in Figure 4A, HSV-2 ICP27 blocks the activation
of the IRF3 responsive promoter induced by SeV.
We next carried out experiments to address whether HSV-
2 ICP27 directly affects the IRF3 signaling pathway. HEK 293T
cells were seeded in 24-well plates overnight and co-transfected
with a plasmid expressing IRF3 signaling pathway component
RIG-IN, MAVS, TBK1, IKK-ε, or IRF3-5D and HSV-2 ICP27
expressing plasmid or empty vector pcDNA3.1(+), together with
the reporter plasmid p125-Luc and the internal control phRL-TK.
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FIGURE 1 | HSV-2 ICP27 inhibits IFN-β production in human mucosal epithelial cells. (A) HSV-2 inhibits IFN-β production in human cervical tissues. Human cervical
tissues were prepared and infected with or without HSV-2. At 4 h.p.i, the tissues were stimulated with or without 100 HAU ml−1 SeV for 16 h, and the supernatants
were harvested for ELISA. (B) HSV-2 ICP27 inhibits the activation of the IFN-β promoter. HEK 293T cells were seeded in 24-well plates and co-transfected with empty
vector pcDNA3.1(+), HSV-2 ICP27 or influenza virus NS1 expressing plasmid, together with the reporter plasmid p125-Luc and the internal control phRL-TK. At 24 h
post-transfection, cells were stimulated with or without 100 HAU ml−1 SeV for 16 h and lysed for DLR assay. (C,D) HSV-2 ICP27 inhibits IFN-β production at both
mRNA and protein levels. HEK 293T cells were seeded in 6-well plates and transfected with empty vector pcDNA3.1(+), plasmid expressing HSV-2 ICP27 or influenza
virus NS1. At 24 h post-transfection, cells were stimulated with or without 100 HAU ml−1 SeV for 16 h and total RNAs were extracted for RT-PCR (C), while the
supernatants were harvested for ELISA (D). (E) HSV-2 inhibits the Poly(I:C)-induced activation of the IFN-β promoter. HeLa cells were seeded in 6-well plates and
co-transfected with empty vector pcDNA3.1(+), plasmid expressing HSV-2 ICP27, ICP22 or the influenza virus NS1, together with the reporter plasmid p125-Luc and
the internal control phRL-TK. At 24 h post-transfection, cells were transfected with 2 µg/well Poly(I:C) or mock-transfected for 16 h and lysed for DLR assay. (F)
HSV-2 ICP27 inhibits Poly(I:C)-induced IFN-β production at protein level. HeLa cells were seeded in 6-well plates and transfected with empty vector pcDNA3.1(+),
plasmid expressing HSV-2 ICP27 or ICP22. At 24 h post-transfection, cells were transfected with 2 µg/well Poly(I:C) or mock-transfected for 16 h, and the
supernatants were harvested for ELISA. (G–I) HSV-2 ICP27 inhibits the production of ISGs. HEK 293T cells were seeded in 6-well plates and transfected with empty
vector pcDNA3.1(+) or HSV-2 ICP27 expressing plasmid. At 24 h post-transfection, cells were stimulated with or without 100 HAU ml−1 SeV for 16 h and lysed for
RT-PCR to measure the expression of ISG56 (D), ISG15 (E), and CXCL10 (F) at the mRNA level. The data shown are representative of three independent
experiments, with each condition performed in triplicate (mean ± SD) (A–I). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
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FIGURE 2 | HSV-2 ICP27 inhibits IFN-β production in the context of virus infection. (A) Knockdown of ICP27 reduces the capability of HSV-2 in inhibiting the IFN-β
promoter activation. HeLa cells were seeded in 6-well plates and co-transfected with HSV-2 ICP27 siRNA-1, siRNA-2, or negative control siRNA (N), together with the
reporter plasmid p125-Luc and the internal control phRL-TK. At 4 h post-transfection, cells were infected with HSV-2 at an MOI of 1 or mock-infected. At 20 h.p.i,
cells were stimulated with or without 100 HAU ml−1 SeV for 16 h and lysed for DLR assay. (B) Knockdown of ICP27 reduces the capability of HSV-2 in inhibiting the
IFN-β production at the protein level. HeLa cells were seeded in 6-well plates and transfected with HSV-2 ICP27 siRNA-1, siRNA-2, or negative control siRNA (N). At
4 h post-transfection, cells were infected with HSV-2 at an MOI of 1 or mock-infected. At 20 h.p.i, cells were stimulated with or without 100 HAU ml−1 SeV for 16 h,
and the supernatants were harvested for ELISA. (C) Knockdown efficiency of HSV-2 ICP27 siRNA. HeLa cells were seeded in 6-well plates and transfected with
HSV-2 ICP27 siRNA-1, siRNA-2, or negative control siRNA (N). At 4 h post-transfection, cells were infected with HSV-2 at an MOI of 1 or mock-infected. At 20 h.p.i,
cells were stimulated with or without 100 HAU ml−1 SeV for 16 h and lysed for Western Blot. Gray scale scanning was performed by Image J software (version 1.52a).
The data shown are representative of three independent experiments, with each condition performed in triplicate (mean ± SD) (A,B). *P < 0.05; ***P < 0.001. One
representative experiment out of three is shown (C).
As shown in Figures 4B–F, HSV-2 ICP27 blocks the activation
of the IFN-β promoter induced by all the tested IRF3 signaling
pathway components in a dose-dependent manner.
Altogether, the above results indicate that, unlike HSV-1
ICP27, HSV-2 ICP27 inhibits IFN-β induction through an IRF3
dependent pathway.
HSV-2 ICP27 Blocks IRF3 Activation by
Physically Interacting With IRF3
There are two main steps involved in IRF3 activation,
phosphorylation and nuclear translocation (12). We first
investigated whether HSV-2 ICP27 interferes with IRF3 nuclear
translocation. Hela cells were seeded in 35mm glass-bottom
dishes overnight and transfected with plasmid expressing
HSV-2 ICP27-HA or influenza virus NS1, or empty vector
pcDNA3.1(+). At 24 h post-transfection, cells were stimulated
with or without 100 HAU ml−1 SeV for 16 h. Indirect
immunofluorescence assay was performed to assess IRF3
localization in the presence or absence of HSV-2 ICP27. As
shown in Figure 5A, IRF3 translocation from the cytoplasm to
the nucleus was partially blocked in the presence of HSV-2 ICP27.
Subsequent experiments were conducted to examine whether
HSV-2 ICP27 blocks the phosphorylation of IRF3. HEK 293T
cells were seeded in 6-well plates overnight and transfected
with plasmid expressing HSV-2 ICP27 or influenza virus
NS1, or empty vector. At 24 h post-transfection, cells were
stimulated with or without 100 HAU ml−1 SeV for 16 h.
The phosphorylation of IRF3 was detected by an anti-p-
IRF3 Ab, showing that HSV-2 ICP27 significantly inhibited
IRF3 phosphorylation in cells (Supplementary Figure 2), and
particularly in the nucleus (Figure 5B).
We next asked whether there is an interaction between
HSV-2 ICP27 and IRF3. Co-immunoprecipitation (Co-IP) was
therefore carried out. HEK 293T cells were seeded in 6-well plates
overnight and transfected with plasmid expressingHSV-2 ICP27-
Flag or empty vector pcDNA3.1(+). At 24 h post-transfection,
cells were stimulated with or without 100HAUml−1 SeV for 16 h,
followed by Co-IP with a control IgG or an anti-Flag Ab. The
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FIGURE 3 | HSV-2 ICP27 inhibits IFN-β production in primary mucosal epithelial cells. (A,B) HSV-2 ICP27 inhibits IFN-β production in human foreskin epithelial cells.
Primary epithelial cells were isolated from human foreskin tissues and transfected with empty vector pcDNA3.1(+), plasmid expressing HSV-2 ICP27 or ICP22 or
infected with HSV-2. At 24 h post-transfection, cells were stimulated with or without 100 HAU ml−1 SeV for 16 h, and total RNAs were extracted for RT-PCR (A), while
the supernatants were harvested for ELISA (B). The data shown are representative of three independent experiments, with each condition performed in triplicate
(mean ± SD) (A,B). *P < 0.05; **P < 0.01.
precipitates were analyzed by Western Blot using an anti-IRF3
Ab against endogenous IRF3. As shown in Figure 5C, HSV-2
ICP27 was able to specifically precipitate the endogenous IRF3,
indicating a physical interaction betweenHSV-2 ICP27 and IRF3.
To further confirm the interaction between IRF3 and ICP27, we
purified ICP27 and IRF3 proteins, and carried out binding kinetic
analyses. A biotinylated IRF3-Flag was coupled to Biosenors
and immersed in different concentrations of the ICP27-Flag for
association and disassociation. As shown in Figure 5D, there
was a strong association between IRF3 and ICP27, and a higher
concentration of ICP27 resulted in a stronger association.
Altogether these results indicate that HSV-2 ICP27
antagonizes the IRF3 signaling pathway by interacting with IRF3.
The 1-138aa Domain of HSV-2 ICP27 Is
Mainly Responsible for the Inhibition of
IFN-β Induction
To map the functional region of HSV-2 ICP27 involved in the
inhibition of IFN-β production, we constructed several HSV-
2 ICP27 truncation mutants according to its structure (https://
www.uniprot.org/uniprot/P28276) (Figure 6A). HEK 293T cells
were co-transfected with empty vector pcDNA3.1(+), truncated
or full-length HSV-2 ICP27 expressing plasmid, with the reporter
plasmid p125-Luc and the internal control phRL-TK. At 24 h
post-transfection, cells were stimulated with or without 100
HAU ml−1 SeV for 16 h and lysed for DLR assay. To measure
IFN-β at protein level, HEK 293T cells were transfected with
empty vector pcDNA3.1(+), truncated or full-length HSV-2
ICP27 expressing plasmid, followed by stimulation with or
without 100 HAU ml−1 SeV for 16 h, and supernatants were
harvested for ELISA. As shown in Figures 6B,C, the 1-138aa
domain of HSV-2 ICP27 significantly inhibited IFN-β induction
at both promoter activation and protein levels, and the capability
was comparable to that of the full-length HSV-2 ICP27. The
expression of ICP27 mutants was confirmed by Western Blot
(Supplementary Figure 3). In contrast to that of HSV-1 ICP27
(30), we did not observe a direct contribution of the RGG box,
which is located in the 138-152aa domain of HSV-2 ICP27, to the
inhibited IFN-β induction. Our findings indicate that the 1-138aa
domain, rather than the RGG box of HSV-2 ICP27 is mainly
responsible for the inhibition of IFN-β induction.
DISCUSSION
HSV-2 is a large enveloped dsDNA virus, and its infections
are known to be restricted to mucosal and keratinized epithelia
and neuronal ganglia. HSV-2 infection causes genital herpes
with sexual transmission being the main route. It is known
that HSV-2 can evade the host mucosal innate immunity, but
the underlying mechanisms remain to be defined (16). Our
current study has demonstrated that HSV-2 immediate early
protein, ICP27, interferes with RIG-I-MAVS-IRF3-mediated
IFN-β induction in mucosal epithelial cells and HEK 293T cells.
Mechanistically, ICP27 directly associates with IRF3 and inhibits
its phosphorylation and nuclear translocation, resulting in the
inhibition of IFN-β induction. Findings in this study reveal an
unconventional strategy exploited by a dsDNA virus to interrupt
the type I IFN signaling pathway.
It is generally accepted that DNA viruses are recognized by
DNA sensors such as TLR9 and cGAS (33), while RNA viruses
are sensed by RNA sensors including TLR3, TLR7/8, RIG-I
and MDA5 (34, 35). Indeed, a number of studies on HSV-
1 reported that the virus can interfere with the cGAS-STING
pathway to inhibit type I IFN induction (30, 36–38). Of interest,
we previously found that HSV-2 can also interrupt RIG-I-MAVS-
IFN-β pathway in human mucosal epithelial cells (22). One
explanation is that, DNA viruses produce dsRNAs during their
replication cycles, which can be recognized by RNA sensors
like RIG-I (31, 32). In addition, STING has also been reported
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FIGURE 4 | HSV-2 ICP27 inhibits IFN-β production through IRF3 signaling pathway. (A) HSV-2 ICP27 inhibits the IRF3 promoter element PRD(III-I)4. HEK 293T cells
were seeded in 24-well plates and co-transfected with empty vector pcDNA3.1(+), plasmid expressing HSV-2 ICP27 or influenza virus NS1, together with
PRD(III-I)4-Luc and the internal control phRL-TK. At 24 h post-transfection, cells were stimulated with or without 100 HAU ml
−1 SeV for 16 h and lysed for DLR assay.
(B–F) HSV-2 ICP27 inhibits RIG-I, MAVS, TBK1, IKK-ε, or IRF3-5D induced IFN-β promoter activation in a dose-dependent manner. HEK 293T cells were seeded in
24-well plates and co-transfected with empty vector pcDNA3.1(+) or HSV-2 ICP27 expressing plasmid, and plasmid expressing IRF3 signaling pathway component
RIG-IN, MAVS, TBK1, IKK-ε, or IRF3-5D, together with the reporter plasmid p125-Luc and the internal control phRL-TK. At 40 h post-transfection, cells were lysed for
DLR assay. At the same time, cells were lysed for Western Blot. RIG-I, MAVS, TBK1, IKK-ε, and IRF3-5D were detected by Anti-FLAG Ab while actin was detected by
Anti-actin Ab. The data shown are representative of three independent experiments, with each condition performed in triplicate (mean ± SD) (A–F). *P < 0.05; **P <
0.01; ***P < 0.001; ****P < 0.0001. For Western Blot, one representative experiment out of three is shown (B–F).
to be involved in RNA virus recognition (39). In the case of
HSV-2, its RNAs are rapidly generated during the life cycle of
its primary infection (40), which may represent an important
alternative source of pathogen-associated molecular patterns to
trigger innate immune responses.
HSV-2 and HSV-1 have different initial infection and
transmission sites, with HSV-2 mainly resulting in genital
infections and HSV-1 normally causing orofacial infections (41).
In addition, HSV-2 has a high positive-incidence of infections
and common mucosal transmission routes with HIV-1 (42).
For instance, HSV-2 predominantly infects mucosal epithelial
cells which forms the primary mucosal barriers against HIV-1
infection, and interruption of these barriers may facilitate HIV-
1 transmission (5). In the current study, we found that HSV-
2 can significantly inhibit IFN-β induction in human cervical
tissues. Moreover, by using mucosal epithelial cell lines and
primary mucosal epithelial cells as models, we demonstrated that
HSV-2 ICP27 contributes to such inhibited IFN-β induction.
The significance of HSV-2 ICP27 in inhibiting IFN-β induction
was further confirmed in the context of virus infection by
the specific siRNA knockdown of HSV-2 ICP27, although
knockdown of HSV-2 ICP27 did not fully abolish HSV-2-
mediated inhibition of IFN-β induction. Given the complexity of
the HSV-2 genome encoding at least 74 proteins, it is highly likely
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FIGURE 5 | HSV-2 ICP27 blocks IRF3 activation by physical interaction. (A) HSV-2 ICP27 interferes with the nuclear translocation of IRF3. HeLa cells were seeded in
35mm glass-bottom dishes and transfected with empty vector pcDNA3.1(+), plasmid expressing HSV-2 ICP27-HA or influenza virus NS1-HA. At 24 h
post-transfection, cells were stimulated with or without 100 HAU ml−1 SeV for 16 h and prepared for immunofluorescence assay. IRF3 was detected under 647 nm
wavelength, ICP27-HA or NS1-HA under 488 nm wavelength, and nuclei under 405 nm wavelength. (B) HSV-2 ICP27 inhibits IRF3 phosphorylation. HEK 293T cells
were seeded in 6-well plates and transfected with pcDNA3.1(+), plasmid expressing HSV-2 ICP27 or influenza virus NS1. At 24 h post-transfection, cells were
stimulated with or without 100 HAU ml−1 SeV for 16 h. Nuclear and cytoplasmic proteins were isolated, and phosphorylated IRF3 was detected with a p-IRF3 mAb.
(C) HSV-2 ICP27 interacts with endogenous IRF3. HEK 293T cells were seeded in 6-well plates and transfected with pcDNA3.1(+) or HSV-2 ICP27-Flag. At 24 h
post-transfection, cells were stimulated with or without 100 HAU ml−1 SeV for 16 h and lysed for immunoprecipitation assay. One representative experiment out of
three is shown (A–C). (D) Kinetics of ICP27-IRF3 binding. The kinetics of binding was performed on a Forte-Bio Octet Red System. Purified IRF3 was conjugated with
biotin at a molecular weight ratio of 1:3. Ten microgram/milliliter biotinylated IRF3-Flag was coupled to Biosenors and immersed in different concentration of
ICP27-Flag (50, 200, 500, or 800 nM) for association and disassociation. The response in nm shift was recorded as a function of time. KD (M) = 2.03E-08.
that other unidentified HSV-2 proteins may also contribute to
the suppression of IFN-β production. Because of the importance
of IFN-β in inhibiting SHIV mucosal transmission (43), future
studies are warranted to investigate whether HSV-2 infection-
mediated IFN-β reduction plays a role in enhancing HIV-1
genital transmission.
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FIGURE 6 | Mapping the key domain of HSV-2 ICP27 that inhibits IFN-β production. (A) Illustration of HSV-2 ICP27 structural domain. 110-138aa is the nuclear
localization signal of ICP27; 138-152aa is the RGG-box domain; 303-509aa is the Herpesvirus transcriptional regulator family UL69; 400-488aa is the zinc ring finger
domain. (B) The 1-138aa domain of ICP27 inhibits the IFN-β promoter activation. HEK 293T cells were seeded in 24-well plates and co-transfected with empty vector
pcDNA3.1(+), plasmid expressing HSV-2 ICP27 or its truncation mutant, together with the reporter plasmid p125-Luc and the internal control phRL-TK. At 24 h
post-transfection, cells were stimulated with or without 100 HAU ml−1 SeV for 16 h and lysed for DLR assay. (C) The 1-138aa domain of ICP27 inhibits IFN-β
induction at protein level. HEK 293T cells were seeded in 24-well plates and transfected with empty vector pcDNA3.1(+), plasmid expressing HSV-2 ICP27 or its
truncation mutant. At 24 h post-transfection, cells were stimulated with or without 100 HAU ml−1 SeV for 16 h, and supernatants were harvested for ELISA. The data
shown are representative of three independent experiments, with each condition performed in triplicate (mean ± SD) (A,B). *P < 0.05; **P < 0.01; ***P < 0.001.
We revealed in the current study that HSV-2 ICP27 can
inhibit IFN-β production via the RIG-I-MAVS pathway. HSV-
1/2 ICP27 is an essential multifunctional immediate early
protein which regulates viral gene expression (44, 45). To date,
most of the studies on ICP27 have focused on HSV-1 (44–
46). For instance, HSV-1 ICP27 was shown to inhibit the
phosphorylation and accumulation of STAT-1 in the nucleus,
resulting the interruption of type I IFN signaling (47). In
agreement, HSV-1 ICP27 knockout enhanced the activation
of IRF3 and NF-κB in macrophages and DCs (48). More
recently, HSV-1 ICP27 has been reported to inhibit type I IFN
induction by interfering with the cGAS–STING–TBK1 signaling
pathway in human macrophages (30). However, HSV-1 ICP27
appeared not to interfere with TBK1 phosphorylation, and the
association of HSV-1 ICP27 with TBK1 required STING (30).
In agreement, we found that, HSV-2 ICP27 strongly inhibited
the production of IFN-β in HEK 293T cell line (22), which does
not express STING (49), further strengthening that HSV-2 ICP27
can inhibit IFN production through a cGAS–STING–TBK1
independent pathway.
IRF3 plays a crucial role in type I IFN-mediated antiviral
immune response (50). Activation of IRF3 during IFN-β
production has several key steps: phosphorylation, dimerization,
and cytoplasm-to-nucleus translocation. We previously found
that, HSV-2 ICP22 inhibits IFN-β induction by antagonizing the
association of IRF3 with the IFN-β promoter without suppressing
the phosphorylation and nuclear translocation of IRF3 (22).
Unlike the mechanism used by HSV-2 ICP22, we demonstrated
in the current study that HSV-2 ICP27 interacts with IRF3 and
interferes with IRF3 activation by blocking IRF3 phosphorylation
and nuclear translocation, thereby inhibiting the production
of IFN-β and ISGs. Given the complexity of HSV-2 genome
containing over 70 genes, it is probable that multiple HSV-2
components likely contribute to the suppression of type I IFN
induction byHSV-2. Indeed, although our current understanding
of HSV-2 immune evasion is limited, work on HSV-1 has
revealed multiple countermeasures in subverting type I IFN
production (17, 18). By designing and analyzing HSV-2 ICP27
truncation mutants, we found that the 1-138aa region of HSV-
2 ICP27 is the key functional domain responsible for HSV-2
Frontiers in Immunology | www.frontiersin.org 11 February 2019 | Volume 10 | Article 290
Guan et al. HSV-2 ICP2 Inhibits IFN-β Production
FIGURE 7 | A schematic model of the mechanism by which HSV-2 ICP27
inhibits IFN-β production. HSV-2 dsRNA is detected by RIG-I, which recruits
MAVS and downstream TBK1 and IKK-ε complex. HSV-2 ICP27 interacts with
IRF3 and interferes with IRF3 activation by blocking IRF3 phosphorylation and
nuclear translocation, thereby inhibiting the production of IFN-β and ISGs.
ICP27-mediated IFN-β reduction. In contrast, a study on HSV-
1 ICP27 has shown that its RGG box, which is located in the
region of 139-152aa, is the main determinant antagonizing the
cytosolic DNA-stimulated IFN-β production, by targeting TBK1
and STING (30). Although HSV-2 ICP27 shares 79% of amino
acid sequence with HSV-1 ICP27, the key function domain,
the N-terminus is only 65% identical, which may explain the
differences in biological functions. For instance, compared with
HSV-1 ICP27, HSV-2 ICP27 is less efficient in promoting the
cytoplasmic localization of ICP4, another important immediate
early protein of HSV 1/2 (44). In addition, the capability of HSV-
2 ICP27 in inhibiting IFN-β production appeared to be much
stronger than that of HSV-1 ICP27 when the ICP27 of HSV-1
was replaced with HSV-2 ICP27 (30), indicating the distinction
of HSV-2 ICP27 in inhibiting IFN-β production.
In conclusion, we have demonstrated that HSV-2
ICP27 inhibits IFN-β induction in human cervical tissues,
cervicovaginal epithelial cell lines, and primary human mucosal
epithelial cells. We further addressed the underlying mechanism
and proposed one model based on the RIG-I-MAVS-IRF3
pathway (Figure 7). During HSV-2 infection of mucosal
epithelial cells, a number of by-products, such as viral dsRNA,
are yielded and can be recognized by the RIG-I receptor. RIG-I
binds to dsRNA through the helicase domain and signals
through caspase activation and recruitment domains to the
adaptor MAVS. Engagement of RIG-I initiates signaling through
two downstream protein kinase complexes, TBK-1/IKK-ε,
leading to the phosphorylation and dimerization of IRF3. IRF3
dimers translocate from the cytoplasm into the nucleus to bind
to the IFN-β promoter, and promote IFN-β transcription (51).
On the other hand, HSV-2 immediate early protein ICP27
interacts with IRF3, and interferes with IRF3 phosphorylation
and nuclear translocation, thereby inhibiting the production of
IFN-β and ISGs. Our findings provide important information
for understanding how HSV-2 evades mucosal innate immunity
and a potential viral target for intervention.
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